AFP and neoplasm: Building on this, the modified Risk Estimation of Tumour Recurrence After Transplant (mRETREAT) score augments RETREAT with AFP-L3 and DCP, improving AUC and calibration; early single-centre data suggest AFP-L3 ≥ 15% and DCP ≥ 7.5 ng/mL at LT enrich for early recurrence and may refine surveillance intensity and adjuvant-trial eligibility [115,116].